07.14.15
Headquarters: Deerfield, IL
twitter.com/baxter
www.baxter.com
TOP SELLING DRUGS
Baxter Bioscience, which will become Baxalta following its separation from Baxter International in mid-2015, plans to continue its efforts in its core strategic areas of hematology and immunology. Each year these therapies see steady growth, and in 2014 hemophilia and biotherapeutic product sales were up 8% and 5%, respectively. Baxalta will have new headquarters in Bannockburn, IL and approximately $6 billion in global revenues to start.
In line with this strategic focus, Baxter divested its Vero cell vaccine platform and related assets, including its production facility in Bohumil, Czech Republic, to Nanotherapeutics. The sale included vaccines for H5N1, H1N1 and seasonal flu. Baxter also sold its commercial vaccines business and related manufacturing facilities to Pfizer for $635 million. This sale included NeisVac-C, to protect against group C meningitis, and FSME-IMMUN, which helps protect against tick-borne encephalitis (TBE).
With continued growth in 2014, and to support its new bioscience business, Baxter is establishing a new global innovation and R&D center in Cambridge, MA. In addition to its core areas, the R&D center will explore technology platforms such as gene therapy and biosimilars.
In August, Baxter opened its first advanced recombinant biologic facility in Singapore, and plans to expand with a new recombinant protein-processing suite, a venture that will create 450 biopharma jobs in Singapore this year. The current suite supports the processing of ADVATE, the company’s recombinant factor VIII (rFVIII) for the treatment of patients with hemophilia A. A second suite will initially process RIXUBIS, a recombinant factor IX (rFIX) protein for the treatment hemophilia B, and when operational, it will be the primary global commercial processing facility. It will also support production of the company’s investigational extended half-life recombinant FVIII treatment upon regulatory approval.
Further expanding its oncology assets, Baxter acquired Sigma-Tau’s Oncaspar portfolio for $900 million, gaining its leading biologic for acute lymphoblastic leukemia (ALL), along with the investigational calaspargase pegol, which is in development for the treatment of ALL with an increased shelf life that’s expected to reduce dosing frequency, along with an established oncology infrastructure with clinical and sales resources. The acquisition expands Baxter’s oncology portfolio, which has an estimated
$10 billion total market potential across current oncology indications.
twitter.com/baxter
www.baxter.com
Headcount: | 61,000 | |
Year Established: | 1931 | |
Revenues: | $16,671 | (+11%) |
Bioscience Revenues: | $6,699 | (+7%) |
Net Income: | $2,497 | (+24%) |
R&D: | $1,421 | (+22%) |
TOP SELLING DRUGS
Drug | 2014 Sales | (+/-%) |
Hemophilia | $3,728 | 8% |
BioTherapeutics | $2,224 | 5% |
BioSurgery | $747 | 4% |
Baxter Bioscience, which will become Baxalta following its separation from Baxter International in mid-2015, plans to continue its efforts in its core strategic areas of hematology and immunology. Each year these therapies see steady growth, and in 2014 hemophilia and biotherapeutic product sales were up 8% and 5%, respectively. Baxalta will have new headquarters in Bannockburn, IL and approximately $6 billion in global revenues to start.
In line with this strategic focus, Baxter divested its Vero cell vaccine platform and related assets, including its production facility in Bohumil, Czech Republic, to Nanotherapeutics. The sale included vaccines for H5N1, H1N1 and seasonal flu. Baxter also sold its commercial vaccines business and related manufacturing facilities to Pfizer for $635 million. This sale included NeisVac-C, to protect against group C meningitis, and FSME-IMMUN, which helps protect against tick-borne encephalitis (TBE).
With continued growth in 2014, and to support its new bioscience business, Baxter is establishing a new global innovation and R&D center in Cambridge, MA. In addition to its core areas, the R&D center will explore technology platforms such as gene therapy and biosimilars.
In August, Baxter opened its first advanced recombinant biologic facility in Singapore, and plans to expand with a new recombinant protein-processing suite, a venture that will create 450 biopharma jobs in Singapore this year. The current suite supports the processing of ADVATE, the company’s recombinant factor VIII (rFVIII) for the treatment of patients with hemophilia A. A second suite will initially process RIXUBIS, a recombinant factor IX (rFIX) protein for the treatment hemophilia B, and when operational, it will be the primary global commercial processing facility. It will also support production of the company’s investigational extended half-life recombinant FVIII treatment upon regulatory approval.
Further expanding its oncology assets, Baxter acquired Sigma-Tau’s Oncaspar portfolio for $900 million, gaining its leading biologic for acute lymphoblastic leukemia (ALL), along with the investigational calaspargase pegol, which is in development for the treatment of ALL with an increased shelf life that’s expected to reduce dosing frequency, along with an established oncology infrastructure with clinical and sales resources. The acquisition expands Baxter’s oncology portfolio, which has an estimated
$10 billion total market potential across current oncology indications.